Myomancy ADHD, Dyslexia and Autism

January 2008

BROKERWATCH Shire's target price cut to 930 pence by Credit Suisse - Trading Markets (press release)

UK Stocks Fall, Led by Royal Bank, Barclays, Standard Life - Bloomberg

FTSE 100 movers: Rio up on revised offer gossip - ShareCast

Broker snap: Goldman downgrades Shire on Vyvanse concerns - ShareCast

Analyst downgrades: SHPGY, IRE and WAG - BloggingStocks

Newspaper wrap-up: Potential crackdowns forced Countrywide to seek … - BloggingStocks

Shire hit by fears over hyperactivity drug - Times Online

Shire plunges on concerns about demand for key drug - Telegraph.co.uk

UK, Irish Stocks Decline, Led by Banks; Shire Retreats - Bloomberg

European Shares Sink with Fed on Horizon - CNBC

BROKERWATCH Shire cut to 'underperform' vs 'market perform' at … - Trading Markets (press release)

CNS Field Reviewed by NeuroInvestment - CNNMoney.com

Shire initiated with "buy" - newratings.com

UK Stocks Advance, Led by Shell, BP, Barclays, Bovis Homes - Bloomberg

Shire upgraded to "outperform" - newratings.com

Students caught selling ADD drug - Goldsboro News Argus

Shire (SHPGY) NewsBite - Shire Lifted by Upgrade - Market Intelligence Center

Students Charged With Selling Drugs At School - WITN TV

Shire Reports FDA Approval Of Additional Dosage Of Vyvanse For … - RTT News

Shire gets FDA approval for three extra dosages of Vyvanse, an … - CNNMoney.com

Shire: FDA OKs New Vyvanse Dosages - CNNMoney.com

FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment … - CNNMoney.com

Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking … - CNNMoney.com

II-VI Inc. Buys Majority Interest In HIGHYAG Lasertechnologie GmbH … - RTT News

FDA Approves Additional Dosage Strengths of Shire's ADHD Treatment … - FOX News

Shire wins US approval for more Vyvanse dosages - Reuters

New drugs for the new year - Ocala.com

December 2007

Shire Expands its Gastrointestinal Portfolio Through In-Licensing … - PR Newswire (press release)

Shire plc: Board Changes - Earthtimes

Shire Expands its Gastrointestinal Portfolio Through In-Licensing … - Earthtimes

Nationwide Survey Reveals Differing Physician and Patient … - Reuters

Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking … - Reuters

ADHD therapy bill looks set to rocket - Pharma Times (subscription)

Zacks Industry Rank Analysis Highlights: Anheuser-Busch, Boston … - Business Wire (press release)

Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD … - CNNMoney.com

Research and Markets: Shire Spends over Us$8 Billion on … - Business Wire (press release)

Shire's QIII earnings top forecast - Checkbiotech.org (press release)

UPDATE 1-Shire Q3 tops forecast, ups revenue outlook - Reuters.uk

Shire Third-Quarter Net Falls 60 Percent on Payment (Update1) - Bloomberg

November 2007

shire goes from strength to strength with its adhd drugs - Pharma Times (subscription)

results of vyvanse(tm) (lisdexamfetamine dimesylate) pivotal trial … - PR Newswire (press release)

results of vyvanse (lisdexamfetamine dimesylate) pivotal trial in … - PR-USA.net (press release)

Rising drug expenditures for ADHD - News-Medical.net

Dramatic Hike Forecast For ADHD Drugs Spend - Science Daily (press release)

Dramatic hike forecast for ADHD drugs spend - EurekAlert (press release)

Shire Reveals Effect Size Of Attention Deficit Hyperactivity … - RTT News

Results Of VYVANSE (Lisdexamfetamine Dimesylate) Effect Size … - PR-USA.net (press release)

Shire lifts FY sales growth outlook after underlying Q3 profit … - Hemscott

Shire has its 'best result in history' - Telegraph.co.uk

Shire: Vyvanse shown effective in Phase III pivotal trial - Trading Markets (press release)